CRIS
$0.54
Curis
$.01
1.89%
CRIS
Earnings Whisper ®
N/A
1st Quarter March 2018
Consensus:  ($0.08)
Revenue:  $2.30 Mil
Thursday
Jun 7
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CRIS reports earnings?
Beat
Meet
Miss

Where is CRIS's stock price going from here?
Up
Flat
Down
Stock chart of CRIS
Analysts
Summary of analysts' recommendations for CRIS
Score
Grade
Pivots
Resistance
$0.58
$0.57
$0.55

$0.54

Support
$0.52
$0.51
$0.49
Tweet
Growth
Description
Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.
Peers
BiogenAmgenGilead SciencesBluebird BioNeurocrine BiosciencesSeattle GeneticsQiagen N.V.BioCryst PharmaceuticalsNovavaxRepligen